Floatz logo

Carboplatin

Atypical Teratoid/Rhabdoid Tumor (AT/RT)

Masonic Cancer Center, University of MinnesotaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Atypical Teratoid/Rhabdoid Tumor (AT/RT) cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2B
Cyclophosphamide
Medical University of Vienna
Phase 2CCC
Fenofibric Acid
Medical University of Vienna
Phase 2CCC
Cytosin-Arabinosid
Medical University of Vienna
Phase 2CCC
Panobinostat
Australian & New Zealand Children's Haematology/Oncology Group
Phase 2CCC

View all 39 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →